阿尔茨海默病治疗曙光初现

In the dawn of curing for Alzheimer’s disease

阿尔茨海默病(Alzheimer's disease,AD)是一种与每个人都息息相关的严重神经变性疾病,其广泛流行带来沉重的社会负担。随着人口老龄化,其发生率还在持续上升。传统药物仅能暂时缓解AD的某些症状,不能延缓该病的恶化进程。近20年来,无数个试图延缓该病恶化进程的AD药物研发在临床试验阶段都以失败告终。长期以来,AD被认为是一种不治之症。目前,靶向淀粉样蛋白(Aβ)药物仑卡奈单抗首次在随机、双盲、多中心的3期临床实验中展现出了延缓AD进程的效果,表明AD是一种可以治疗的疾病,而异常聚集的Aβ就是一个致病原因。该进展对于AD的致病理论和治疗同时具有划时代的伟大意义,开启了人类攻克AD的新纪元。在本述评中,我们对AD研究的前沿进展进行总结,旨在提高社会对该病的关注和理解。

Alzheimer's Disease(AD)is a devastating neurodegenerative condition that warrants attention from all individuals,given its widespread prevalence and profound societal burden.As the population of elderly individuals continues to rise,the incidence of AD is steadily increasing.Conventional pharmacotherapeutic interventions offer only transient amelioration of certain AD symptoms,failing to halt the inexorable progression of the disease.Over the past two decades,extensive efforts have been made to develop anti-AD drugs with disease modifying potentials but all of which have been failed.Consequently,AD has long been perceived as an incurable affliction.However,lecanemab,a monoclonal antibody that targets aggregated amyloid-beta(Aβ),has demonstrated efficacy in slowing the progression of AD in a rigorously conducted randomized,double-blind,multi-center phase 3 clinical trial.This landmark advancement signifies AD as a modifiable condition,with aberrant Aβaggregation serving as a pivotal etiological factor.This breakthrough holds epochal significance for both theoretical understanding and therapeutic modalities,heralding a transformative epoch in humanity's pursuit to conquer AD.In this review,we endeavor to summarize the cutting-edge advancements in AD research,with the aim of augmenting societal awareness and comprehension of this disease.